Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases

被引：31

作者：

Blomgren, Peter ^{[1
]}

Chandrasekhar, Jayaraman ^{[1
]}

Di Paolo, Julie A. ^{[2
]}

Fung, Wanchi ^{[2
]}

Geng, Guoju ^{[2
]}

Ip, Carmen ^{[2
]}

Jones, Randall ^{[1
]}

Kropf, Jeffrey E. ^{[1
]}

Lansdon, Eric B. ^{[2
]}

Lee, Seung ^{[1
]}

Lo, Jennifer R. ^{[1
]}

Mitchell, Scott A. ^{[1
]}

Murray, Bernard ^{[2
]}

Pohlmeyer, Chris ^{[2
]}

Schmitt, Aaron ^{[1
]}

Suekawa-Pirrone, Kimberly ^{[2
]}

Wise, Sarah ^{[2
]}

Xiong, Jin-Ming ^{[1
,2
]}

Xu, Jianjun ^{[1
,2
]}

Yu, Helen ^{[2
]}

Zhao, Zhongdong ^{[1
,2
]}

Currie, Kevin S. ^{[1
]}

机构：

[1] Gilead Sci, Seattle, WA 98102 USA

[2] Gilead Sci, Foster City, CA 94404 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 04期

关键词：

SYK; kinase inhibitor; solubility; lupus; SYK; ENTOSPLETINIB; GS-9973; POTENT;

D O I：

10.1021/acsmedchemlett.9b00621

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Spleen tyrosine kinase (SYK) is a critical regulator of signaling in a variety of immune cell types such as B-cells, monocytes, and macrophages. Accordingly, there have been numerous efforts to identify compounds that selectively inhibit SYK as a means to treat autoimmune and inflammatory diseases. We previously disclosed GS-9973 (entospletinib) as a selective SYK inhibitor that is under clinical evaluation in hematological malignancies. However, a BID dosing regimen and drug interaction with proton pump inhibitors (PPI) prevented development of entospletinib in inflammatory diseases. Herein, we report the discovery of a second-generation SYK inhibitor, GS-9876 (lanraplenib), which has human pharmacokinetic properties suitable for once-daily administration and is devoid of any interactions with PPI. Lanraplenib is currently under clinical evaluation in multiple autoimmune indications.

引用

页码：506 / 513

页数：8

共 50 条

[11] Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
Link, John O.
Taylor, James G.
Xu, Lianhong
Mitchell, Michael
Guo, Hongyan
Liu, Hongtao
Kato, Darryl
Kirschberg, Thorsten
Sun, Jianyu
Squires, Neil
Parrish, Jay
Keller, Terry
Yang, Zheng-Yu
Yang, Chris
Matles, Mike
Wang, Yujin
Wang, Kelly
Cheng, Guofeng
Tian, Yang
Mogalian, Erik
Mondou, Elsa
Cornpropst, Melanie
Perry, Jason
Desai, Manoj C.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 2033 - 2046
[12] Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases
Mammoliti, Oscar
Martina, Sebastien
Claes, Pieter
Coti, Ghjuvanni
Blanque, Roland
Jagerschmidt, Catherine
Shoji, Kenji
Borgonovi, Monica
De Vos, Steve
Marsais, Florence
Oste, Line
Quinton, Evelyne
Lopez-Ramos, Miriam
Amantini, David
Brys, Reginald
Jimenez, Juan-Miguel
Galien, Rene
van der Plas, Steven
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 8545 - 8568
[13] Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Gerstenberger, Brian S.
Ambler, Catherine
Arnold, Eric P.
Banker, Mary-Ellen
Brown, Matthew F.
Clark, James D.
Dermenci, Alpay
Dowty, Martin E.
Fensome, Andrew
Fish, Susan
Hayward, Matthew M.
Hegen, Martin
Hollingshead, Brett D.
Knafels, John D.
Lin, David W.
Lin, Tsung H.
Owen, Dafydd R.
Saiah, Eddine
Sharma, Raman
Vajdos, Felix F.
Xing, Li
Yang, Xiaojing
Yang, Xin
Wright, Stephen W.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (22) : 13561 - 13577
[14] TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Hayashi, Hiroaki
Kaneko, Ryuusuke
Tayama, Manabu
Demizu, Shunsuke
Akasaka, Daichi
Irie, Hiroki
Kawagishi, Aki
Ogino, Yoshio
Utsugi, Teruhiro
Sasaki, Eiji
Iwasawa, Yoshikazu
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[15] Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
Lam, Betty
Arikawa, Yasuyoshi
Cramlett, Joshua
Dong, Qing
de Jong, Ron
Feher, Victoria
Grimshaw, Charles E.
Farrell, Pamela J.
Hoffman, Isaac D.
Jennings, Andy
Jones, Benjamin
Matuszkiewicz, Jennifer
Miura, Joanne
Miyake, Hiroshi
Natala, Srinivasa Reddy
Shi, Lihong
Takahashi, Masashi
Taylor, Ewan
Wyrick, Corey
Yano, Jason
Zalevsky, Jonathan
Nie, Zhe
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (24) : 5947 - 5950
[16] Discovery of TAK-659, an orally available investigational inhibitor of spleen tyrosine kinase (SYK)
Lam, Betty
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[17] Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects
Tong Zhu
Barbara Parker
Tomasz Wojtkowski
Tetsuya Nishimura
Jay P. Garg
David Han
Ogert Fisniku
James Keirns
Clinical Pharmacokinetics, 2017, 56 : 747 - 757
[18] Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects
Zhu, Tong
Parker, Barbara
Wojtkowski, Tomasz
Nishimura, Tetsuya
Garg, Jay P.
Han, David
Fisniku, Ogert
Keirns, James
CLINICAL PHARMACOKINETICS, 2017, 56 (07) : 747 - 757
[19] Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
Ma, Bin
Bohnert, Tonika
Otipoby, Kevin L.
Tien, Eric
Arefayene, Million
Bai, Judy
Bajrami, Bekim
Bame, Eris
Chan, Timothy R.
Humora, Michael
MacPhee, J. Michael
Marcotte, Douglas
Mehta, Devangi
Metrick, Claire M.
Moniz, George
Polack, Evelyne
Poreci, Urjana
Prefontaine, Annick
Sheikh, Sarah
Schroeder, Patricia
Smirnakis, Karen
Zhang, Lei
Zheng, Fengmei
Hopkins, Brian T.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (21) : 12526 - 12541
[20] Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor
Liddle, John
Atkinson, Francis L.
Barker, Michael D.
Carter, Paul S.
Curtis, Neil R.
Davis, Rob P.
Douault, Clement
Dickson, Marion C.
Elwes, Dorothy
Garton, Neil S.
Gray, Matthew
Hayhow, Thomas G.
Hobbs, Clare I.
Jones, Emma
Leach, Stuart
Leavens, Karen
Lewis, Huw D.
McCleary, Scott
Neu, Margarete
Patel, Vipulkumar K.
Preston, Alex G. S.
Ramirez-Molina, Cesar
Shipley, Tracy J.
Skone, Philip A.
Smithers, Nick
Somers, Donald O.
Walker, Ann L.
Watson, Robert J.
Weingarten, Gordon G.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (20) : 6188 - 6194

← 1 2 3 4 5 →